Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of VX-440 alone and with tezacaftor and ivacaftor in cystic fibrosis
NL-OMON45508Phase 2Not yet recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ivacaftor and tezacaftor in cystic fibrosis (CF) (5 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Safety and tolerability and Absolute change in ppFEV1. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
ivacaftortezacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON45508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45508.